EP
NVCR icon

Essential Partners’s NovoCure NVCR Stock Holding History

Essential Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.6K Sell
916
-35
-4% -$584 0.01% 1031
2026
Q2 		$14.4K Sell
951
-307
-24% -$4.64K 0.01% 1038
2026
Q1 		$13.7K Buy
1,258
+716
+132% +$8.94K ﹤0.01% 1091
2025
Q4 		$7.01K Buy
542
+130
+32% +$1.67K ﹤0.01% 1296
2025
Q3 		$5.32K Buy
412
+394
+2,189% +$5.26K ﹤0.01% 1402
2025
Q2 		$320 Buy
+18
New +$314 ﹤0.01% 1824

Other funds holding NVCR

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Essential Partners's NVCR Position: Q3 2026 in Review

Essential Partners reduced its NovoCure (NVCR) stake by 3.7% in Q3 2026, selling an estimated $584 and leaving 916 shares worth $14.6K. The position accounts for 0.01% of the portfolio, ranked #1031.

Essential Partners first reported a position in NVCR in Q2 2025 and has held it in 6 quarters since. 15 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Essential Partners held 916 shares of NovoCure worth $14.6K as of Q3 2026.
  • Essential Partners sold 35 NovoCure shares in Q3 2026, an estimated $584.
  • NovoCure made up 0.01% of Essential Partners's portfolio in Q3 2026, its #1031 holding.
  • Essential Partners first reported a position in NovoCure in Q2 2025 and has held it in 6 quarters since.
  • 15 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.